Clinical Trial

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Study acronym: AURORAS-1
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Protocol Amendment History 1 change
notable Enrollment increased: 200 -> 600 participants 2026-06-27
Trial Details
NCT Number NCT06983743
Lead Sponsor Erasca, Inc.
Collaborators: Merck Sharp & Dohme LLC
Conditions Metastatic Solid Tumors
Enrollment 600 participants
Start Date 2025-06-05
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-31